---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-007708"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:32:16.824463+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia

## Summary
- BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.
- BGLC will receive 1.5 million common shares of BirchBioMed in exchange.
- Collaboration to commercialize FS2 (kynurenic acid) topical cream in Malaysia and Singapore.
- Term sheet non-binding except 60-day exclusivity; no assurance definitive agreement will be reached.

## SEC filing metadata
- accession: 0001477932-25-007708
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793225007708/0001477932-25-007708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793225007708/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-007708
- JSON: https://secwatch.observer/filing/0001477932-25-007708.json
- Plain text: https://secwatch.observer/filing/0001477932-25-007708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.